Open AccessNoninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma
Author(s) -
Elena Pope,
Irene LaraCorrales,
Cathryn Sibbald,
Carmen LiyWong,
Nordau Kanigsberg,
Beth A. Drolet,
Jin Ma
Publication year - 2021
Publication title -
jama pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.004
H-Index - 183
eISSN - 2168-6211
pISSN - 2168-6203
DOI - 10.1001/jamapediatrics.2021.4565
Subject(s) - nadolol , medicine , propranolol , adverse effect , infantile hemangioma , timolol , hemangioma , prospective cohort study , pediatrics , anesthesia , surgery , intraocular pressure
Propranolol for infantile hemangiomas (IH) has been shown to be effective and relatively safe. However, other less lipophilic β-blockers, such as nadolol, may be preferable in individuals who experience propranolol unresponsiveness or adverse events.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom